This is a summary of the European public assessment report (EPAR) for Ocrevus. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ocrevus. For practical information about using Ocrevus, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
Therapeutic Area (MeSH)
ATC Code
L04AG08
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ocrelizumab | N/A | ocrelizumab |
EMA Name
Ocrevus
Medicine Name
Ocrevus
Aliases
N/ANo risk management plan link.
